Identification of (E)-1-((1H-indol-3-yl)methylene)-4-substitute-thiosemicarbazones as potential anti-hepatic fibrosis agents

Bioorg Chem. 2024 Feb:143:107022. doi: 10.1016/j.bioorg.2023.107022. Epub 2023 Dec 16.

Abstract

Liver fibrosis remains a global health challenge due to its rapidly rising prevalence and limited treatment options. The orphan nuclear receptor Nur77 has been implicated in regulation of autophagy and liver fibrosis. Targeting Nur77-mediated autophagic flux may thus be a new promising strategy against hepatic fibrosis. In this study, we synthesized four types of Nur77-based thiourea derivatives to determine their anti-hepatic fibrosis activity. Among the synthesized thiourea derivatives, 9e was the most potent inhibitor of hepatic stellate cells (HSCs) proliferation and activation. This compound could directly bind to Nur77 and inhibit TGF-β1-induced α-SMA and COLA1 expression in a Nur77-dependent manner. In vivo, 9e significantly reduced CCl4-mediated hepatic inflammation response and extracellular matrix (ECM) production, revealing that 9e is capable of blocking the progression of hepatic fibrosis. Mechanistically, 9e induced Nur77 expression and enhanced autophagic flux by inhibiting the mTORC1 signaling pathway in vitro and in vivo. Thus, the Nur77-targeted lead 9e may serve as a promising candidate for treatment of chronic liver fibrosis.

Keywords: Autophagy; Hepatic stellate cells activation; Liver fibrosis; Nur77; Thiourea derivatives; mTORC1.

MeSH terms

  • Antifibrotic Agents*
  • Carbon Tetrachloride
  • Hepatic Stellate Cells
  • Humans
  • Liver / metabolism
  • Liver Cirrhosis / metabolism
  • Thiosemicarbazones* / metabolism
  • Thiourea / metabolism

Substances

  • Antifibrotic Agents
  • Thiosemicarbazones
  • Thiourea
  • Carbon Tetrachloride